Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 176

Sort by

Sort Order Select

Journal Articles

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Blood (2025) 146 (Supplement 1): 2562.

https://doi.org/10.1182/blood-2025-2562

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Blood (2025) 146 (Supplement 1): 919.

https://doi.org/10.1182/blood-2025-919

Published: 2025

Journal Articles

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

Marta Lasa, Esperanza Martin-Sanchez, Aintzane Zabaleta, Diego Alignani, Carmen Gonzalez, Noemi Puig, Elena Alejo, Jorge Labrador, Maria Casanova Espinosa, Laura Rosiñol Dachs, Sebastián Garzón, Enrique Ocio, Albert Pérez-Montaña, Irene Romera, Carmen Couto, Sunil Lakhwani, Felipe Prosper, Adrian Alegre, Elena Cabezudo, Itziar Carro, Cristina Motlló, Montserrat Cortes, Isabel Maria Garcia Cabrera, Marta Romera, Javier de la Rubia, Andrea Manubens, Alexia Suarez Cabrera, Fernando Escalante Barrigón, Carlos Aguilar-Franco, Raquel Del Campo, Maria Esther Clavero Sanchez, Joaquin Martinez-Lopez, Valentin Cabanas Perianes, María-Jesús Blanchard, Ana Lopez-Guia, Diana Sanchez Arguello, Albert Oriol, Marta Reinoso -Segura, María Lourdes Amador Barciela, Celina Benavente Cuesta, Jose Maria Arguiñano PEREZ, Beatriz Ordoñez, Francisco Taboada, Joan Batista Blade Creixenti, María-Victoria Mateos, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, Bruno Paiva

Blood (2025) 146 (Supplement 1): 578.

https://doi.org/10.1182/blood-2025-578

Published: 2025

Journal Articles

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2025) 146 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2025-2288

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Blood (2025) 146 (Supplement 1): 494.

https://doi.org/10.1182/blood-2025-494

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Blood (2025) 146 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2025-2238

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro, Diego Alignani, Saioa Vicente, Aitziber Lopez, Ana Alfonso-Pierola, Luis-Esteban Tamariz-Amador, Jesus San-Miguel, Paula Rodriguez-Otero, Felipe Prosper

Blood (2025) 146 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2025-7445

Published: 2025

Journal Articles

Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro, Patxi San Martin-Uriz, Saioa Vicente, Maria Jose Larrayoz, Luis-Esteban Tamariz-Amador, Ana Alfonso-Pierola, Jesus San-Miguel, Maria Calasanz, Paula Rodriguez-Otero, Felipe Prosper

Blood (2025) 146 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2025-6121

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Journal Articles

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Blood (2025) 146 (Supplement 1): 366.

https://doi.org/10.1182/blood-2025-366

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Blood (2025) 146 (Supplement 1): 364.

https://doi.org/10.1182/blood-2025-364

Published: 2025

Journal Articles

Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma

Vianca Ibarra-Garcia, Maria Erendira Calleja-Cervantes, Eva Molina, Franco Bernasconi-Bisio, Federica Rochira, Iñigo Azagra-Barber, Ines Ibañez-Sala, Saray Rodriguez-Diaz, Rebeca Martinez-Turrillas, Lucia Vanrell, Juan Lasarte, Ana Alfonso-Pierola, Paula Rodriguez-Otero, Jesus San-Miguel, Juan Roberto Rodriguez-Madoz, Antonio Pineda-Lucena, Felipe Prosper

Blood (2025) 146 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2025-4072

Published: 2025

Journal Articles

Integrative omics analysis of TP53 in multiple myeloma patients

Cristina De Ramón Sánchez, Elizabeta A Rojas, Irena Misieweicz, Maria García-Alvarez, Myriam Cuadrado, Sara Cristobal, Ignacio J Cardona-Benavides, Isabel M Isidro, Maria Calasanz, Miguel Alcoceba, Ramon Garcia-Sanz, Laura Rosiñol Dachs, Joaquin Martinez-Lopez, Joan Batista Blade Creixenti, Juan-Jose Lahuerta Palacios, Jesus San-Miguel, María-Victoria Mateos, Luis Antonio Corchete Sanchez, Norma Gutiérrez

Blood (2025) 146 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2025-2162

Published: 2025

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Minimally invasive assessment of peripheral residual disease (PRD) during maintenance or observation in patients (Pts) with multiple myeloma (MM): An update from the GEM2017FIT clinical trial

Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the nomoremgus study

A Phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in frailer transplant-ineligible patients with newly diagnosed multiple myeloma

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM)

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies

Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma

Integrative omics analysis of TP53 in multiple myeloma patients

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only